AUTHOR
|
STUDY GROUP (mean change from baseline) | CONTROL GROUP(S) (mean change from base line) |
P-VALUE
|
Ichihara et al(7) (2013) | Mirabegron(50mg) -2.21 + Tamsulosin(0.2mg) |
Tamsulosin(0.2mg) -0.87
|
P - 0.012
|
Kakizaki(8) (2017) | Mirabegron(50mg) -2.78 + Tamsulosin(0.2mg) | Tamsulosin (0.2mg) -2.13 + placebo |
P - 0.001
|
Present study Baseline(mean ± S.D) End point(mean ± S.D) Mean difference | 7.95±2.80 2.33±1.18 -5.62 | 6.75±2.08 4.53±1.88 -2.22 |
P < 0.001
|
OABSS – Overactive bladder symptom score, S.D – Standard deviation. | OABSS – Overactive bladder symptom score, S.D – Standard deviation. | OABSS – Overactive bladder symptom score, S.D – Standard deviation. | OABSS – Overactive bladder symptom score, S.D – Standard deviation. |
TABLE 3b | |||
COMPARISION PREVIOUS SIMILAR STUDY DESIGNS WITH THE PRESENT STUDY WITH RESPECT TO IPSS-S SCORE IMPROVEMENT | TABLE 3b | ||
COMPARISION PREVIOUS SIMILAR STUDY DESIGNS WITH THE PRESENT STUDY WITH RESPECT TO IPSS-S SCORE IMPROVEMENT | TABLE 3b | ||
COMPARISION PREVIOUS SIMILAR STUDY DESIGNS WITH THE PRESENT STUDY WITH RESPECT TO IPSS-S SCORE IMPROVEMENT | TABLE 3b | ||
COMPARISION PREVIOUS SIMILAR STUDY DESIGNS WITH THE PRESENT STUDY WITH RESPECT TO IPSS-S SCORE IMPROVEMENT | |||
AUTHOR
|
STUDY GROUP (mean change from baseline) | CONTROL GROUP(S) (mean change from base line) |
P-VALUE
|
Ichihara et al(7) (2013) | Mirabegron(50mg) -2.03 + Tamsulosin(0.2mg) |
Tamsulosin(0.2mg) -0.42
|
P - 0.006
|
Kakizaki(8) (2017) | Mirabegron(50mg) -2.29 + Tamsulosin(0.2mg) | Tamsulosin (0.2mg) -1.51 + placebo |
P < 0.001
|
Present study Baseline(mean ± S.D) End point(mean ± S.D) Mean difference | 12.68±2.71 3.27±1.26 -9.40 | 10.97±3.02 6.38±2.16 -7.48 |
P < 0.001
|
IPSS-S: IPSS storage subscore, S.D – Standard deviation. | IPSS-S: IPSS storage subscore, S.D – Standard deviation. | IPSS-S: IPSS storage subscore, S.D – Standard deviation. | IPSS-S: IPSS storage subscore, S.D – Standard deviation. |
TABLE 3c | |||
COMPARISION OF SIMILAR STUDIES WITH THE PRESENT STUDY WITH RESPECT TO CHANGE IN PVR | TABLE 3c | ||
COMPARISION OF SIMILAR STUDIES WITH THE PRESENT STUDY WITH RESPECT TO CHANGE IN PVR | TABLE 3c | ||
COMPARISION OF SIMILAR STUDIES WITH THE PRESENT STUDY WITH RESPECT TO CHANGE IN PVR | TABLE 3c | ||
COMPARISION OF SIMILAR STUDIES WITH THE PRESENT STUDY WITH RESPECT TO CHANGE IN PVR | |||
AUTHOR
|
STUDY GROUP (mean change from baseline) | CONTROL GROUP(S) (mean change from the baseline) |
P-VALUE
|
Ichihara et al(7) (2013) | Mirabegron(50mg) 37.3 + Tamsulosin(0.2mg) |
Tamsulosin(0.2mg) 3.9
|
P – 0.020
|
Kakizaki et al (8) (2017) | Mirabegron(50mg) 2.72 + Tamsulosin(0.2mg) | Tamsulosin (0.2mg) -0.97 + placebo |
P - 0.059
|
Present study Baseline(mean ± S.D) End point(mean ± S.D) Mean difference | 58.38±68.79 51.17±51.32 -7.20 | 79.35±119.39 49.08±70.07 -30.27 |
P – 0.136
|
PVR- Post void residual urine, S.D – Standard deviation. | PVR- Post void residual urine, S.D – Standard deviation. | PVR- Post void residual urine, S.D – Standard deviation. | PVR- Post void residual urine, S.D – Standard deviation. |